<DOC>
	<DOCNO>NCT00764478</DOCNO>
	<brief_summary>This trial study efficacy safety fix dose asenapine participant diagnose Bipolar 1 Disorder . Participants qualify study randomly assign receive fix dose asenapine ( either 5 mg 10 mg twice daily [ BID ] ) placebo ( BID ) 3 week . Throughout trial , observation make participant various time assess safety effectiveness study treatment . The primary hypothesis least one dose asenapine superior placebo change baseline manic symptom ( measure Young Mania Rating Scale [ YMRS ] ) Day 21 trial .</brief_summary>
	<brief_title>Fixed-dose Safety Efficacy Study Asenapine Treatment Acute Manic Mixed Episode Bipolar 1 Disorder ( P05691 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Each participant must least 18 year age Male , female childbearing potential nonpregnant , nonlactating , use medically accept method contraception Each participant must current diagnosis Bipolar I Disorder , current episode manic mixed Each participant must confirm experience acute manic mixed bipolar 1 episode Each participant must discontinue use prohibit psychotropic medication A participant must primary Axis I disorder Bipolar 1 Disorder ( i.e. , Axis 1 disorder Bipolar 1 Disorder primarily responsible current symptom functional impairment ) A participant must currently ( within past 6 month ) meet Diagnostic Statistical Manual Mental Disorders Fourth Edition , Text Revision ( DSMIVTRâ„¢ ) criterion substance abuse dependence ( exclude nicotine ) A participant must imminent risk selfharm harm others , investigator 's opinion base clinical interview response provide Columbia Suicide Severity Rating Scale ( CSSRS ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>